What is Omeros?
Omeros is a Seattle-based biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. Their focus spans both large-market and orphan indications, targeting critical areas such as inflammation, coagulopathies, and central nervous system disorders. Founded in 1994, Omeros leverages its expertise in small-molecule and protein therapeutics to address unmet medical needs. The company's commitment to scientific innovation positions it as a key player in the biopharmaceutical landscape, aiming to bring transformative treatments to patients.
How much funding has Omeros raised?
Omeros has raised a total of $1.1B across 22 funding rounds:
Stock Offering
$84M
Multiple Rounds
$215M
Stock Offering
$63.6M
Debt
$210M
Stock Offering
$57.5M
Debt
$92.1M
Other Financing Round
$4M
Stock Issuance/Offering (2015): $84M, investors not publicly disclosed
Debt (2016): $50M backed by East West Bank and Oxford Finance
Stock Issuance/Offering (2016): $40M with participation from Cantor Fitzgerald & Co.
Debt (2016): $125M led by CRG LP
Stock Issuance/Offering (2017): $63.6M, investors not publicly disclosed
Debt (2018): $210M, investors not publicly disclosed
Stock Issuance/Offering (2019): $57.5M, investors not publicly disclosed
Debt (2024): $92.1M with participation from Athyrium Capital Management and Highbridge Capital Management
Other Financing Round (2025): $4M led by National Institute on Drug Abuse
Key Investors in Omeros
Athyrium Capital Management
Athyrium Capital Management is a leading investment management platform focused on structured investments in the global healthcare sector, investing in a diverse array of financial instruments including royalties, structured credit, and equities.
Highbridge Capital Management
Founded in 1992, Highbridge Capital Management is a global alternative investment firm offering hedge fund strategy services and liquidity products, headquartered in New York.
Oxford Finance
Oxford Finance, founded in 2002 and headquartered in Alexandria, Virginia, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide.
What's next for Omeros?
The recent major strategic investment in Omeros suggests a phase of accelerated development and potential market expansion. This capital infusion is likely to fuel further clinical trials, enhance manufacturing capabilities, and support the commercial launch of existing or pipeline assets. As a company with a history of securing substantial financing, Omeros is well-positioned to navigate the complex regulatory and market challenges inherent in the biopharmaceutical industry. Future endeavors will likely focus on advancing their therapeutic candidates through late-stage development and securing necessary approvals for market entry, thereby solidifying their position in the therapeutic areas they serve.
See full Omeros company page
